Full-Time
Associate Product Manager
Updated on 8/23/2026
Ferring Pharmaceuticals
5,001-10,000 employees
Develops peptide hormone-based medicines and therapies
No salary listed
Mumbai, Maharashtra, India
In Person
Bachelor's, MBA
 Product (1) |
|---|
Get referred to Ferring Pharmaceuticals
See people who can refer or advise you
- A Bachelor's degree in Pharmacy, Life Sciences, Biotechnology, or a related field is required.
- At least 3 years of experience in pharmaceutical sales, marketing, brand management, or related commercial roles is required.
- Knowledge of pharmaceutical markets is required.
- Knowledge of brand management and marketing fundamentals is required.
- Experience with data analysis and market research is required.
- Understanding of digital marketing is required.
- Financial and business acumen are required.
- Strong analytical and problem-solving skills are required.
- Strong communication and presentation skills are required.
- Stakeholder management and influencing ability are required.
- Project management and organizational skills are required.
- Collaboration and teamwork skills are required.
- A results-oriented approach is required.
- Support the development and execution of annual brand plans.
- Conduct market analysis, competitor tracking, and performance reviews to identify growth opportunities.
- Monitor brand key performance indicators, including sales performance, market share, prescription trends, and customer engagement.
- Provide insights and recommendations to optimize brand performance.
- Assist in designing and executing promotional campaigns and tactical marketing initiatives.
- Coordinate the development of promotional materials, visual aids, digital content, and marketing collateral.
- Work with creative and digital agencies to ensure timely campaign delivery.
- Ensure promotional activities comply with internal and regulatory guidelines.
- Analyze market trends, customer insights, and the competitive landscape.
- Conduct healthcare professional feedback sessions and market research projects.
- Generate actionable insights to support brand decision-making.
- Partner with the sales team to develop communication tools and promotional strategies.
- Support sales force training on product positioning, key messages, and campaign objectives.
- Monitor field feedback and recommend improvements.
- Collaborate with Medical Affairs, Regulatory Affairs, Market Access, Supply Chain, Finance, and Sales teams.
- Support product launches, line extensions, and lifecycle management activities.
- Participate in cross-functional brand team meetings.
- Assist in planning and executing new product launches.
- Track launch readiness and coordinate launch activities across functions.
- Support portfolio management initiatives and brand lifecycle strategies.
- Support tracking and monitoring of marketing budgets.
- Ensure optimal utilization of promotional investments.
- Work with finance teams on budget forecasting and reconciliation.
- An MBA in Marketing is preferred.
- Prior experience in pharmaceutical product management is desirable.
- Experience with IQVIA or market-intelligence data analysis is preferred.
- Proficiency in PowerPoint, Excel, and dashboard reporting is preferred.
- Understanding of pharmaceutical regulations and promotional compliance is preferred.
- Exposure to omnichannel marketing and digital engagement strategies is preferred.
Ferring Pharmaceuticals develops medicines that use the body's own peptide hormones, focusing on specialties such as reproductive health, gastroenterology, and urology. Its products range from hormone-based therapies to newer gene-based treatments, such as Adstiladrin for bladder cancer. The company achieves its solutions through research-driven development and manufacturing, including synthetic production of peptide hormones (historically oxytocin and vasopressin) and ongoing expansion of production and clinical programs. Ferring differentiates itself by remaining privately held to pursue a long-term research vision, growing through organic expansion and strategic acquisitions while maintaining a global footprint (over 100 countries, 7,000+ employees). Its goal is to advance therapies that leverage the body's biology to treat diseases more effectively, supported by a sustained investment in R&D and manufacturing, with a future focus on bioengineered and gene-based approaches.
Company Size
5,001-10,000
Company Stage
Debt Financing
Total Funding
$302.5M
Headquarters
Saint-Prex, Switzerland
Founded
1950
Get referred to Ferring Pharmaceuticals
See people who can refer or advise you
Simplify's Take
What believers are saying
- 2025 revenue topped €2.5 billion, up 10%, driven mainly by Menopur.
- FDA updated Adstiladrin labeling in 2026, cutting thaw time to 25 minutes.
- Portugal expansion and Theralase collaboration widen manufacturing and bladder-cancer opportunities.
What critics are saying
- Ferring plans 500 layoffs in 2026, including 64 Parsippany cuts.
- Delaware upheld roughly $25.8 million Rebyota patent damages against Ferring in June 2026.
- If Adstiladrin uptake stalls and Menopur softens, Ferring's 2025 growth engine collapses.
What makes Ferring Pharmaceuticals unique
- Private, foundation-owned Ferring invests for decades, not quarterly exit windows.
- Adstiladrin and Menopur anchor defensible niches in bladder cancer and fertility.
- The 2026 Gallup fertility project cements Ferring as a demographic-data authority.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Dental Insurance
Vision Insurance
Disability Insurance
Life Insurance
401(k) Retirement Plan
401(k) Company Match
Wellness Program
Tuition Reimbursement
Paid Sick Leave
Paid Vacation
Paid Holidays
Parental Leave
Hybrid Work Options
Growth & Insights and Company News
6 month growth
↑ 6%1 year growth
↑ 6%2 year growth
↑ 6%Register for the Motility Symposium - 18 september 2026. Posted Monday July 6, 2026 A great day is planned for the 2026 Motility Symposium including sessions on Upper GI and Gastric, Mid/Lower Tract Physiology & Endoscopy, and Systemic * Psychogastroenterology. See the full programme below. Registration for the event is $520.00 and incudes a dinner following the symposium at Ayrburn. Gallery. Monday July 6, 2026 Demo Content Events + 1 More In late July the NZSG Executive Committee will be meeting to consider the Strategic Plan for 2027 to 2032 Monday July 6, 2026 Demo Content Events The 2026 NZSG IBD Symposium is proudly sponsored by Pharmaco and Ferring, taking place in Wellington. Monday July 6, 2026 Demo Content Gastroenterologists across Aotearoa are welcome to participate in a national validation study evaluating an AI assisted...
Cosette Pharmaceuticals names David Bell CCO of brands. Bell is tasked with driving performance across Cosette's marketed portfolio of 21 brands. May 19, 2026 Content Marketing Editor Why This Matters: See our industry-wide coverage of other executive team appointments and promotions here. Cosette Pharmaceuticals is appointing David Bell Chief Commercial Officer (CCO), Brands. Accordingly, Bell will oversee commercial functions for all 21 brands in Cosette's marketed portfolio. This includes sales, marketing, market access, commercial operations, analytics, and portfolio strategy among areas in which Bell will drive performance. According to Cosette, Bell will support integration and growth of acquired assets as the company advances commercial ambitions in specialty pharmaceuticals. Overseeing commercial performance of brands. In the CCO role, Bell will ultimately oversee alignment between Cosette's commercial execution and its broader strategic and financial objectives. "I'm proud to join an organization that has built a differentiated platform [to] help patients live better lives," Bell said. He emphasized his excitement in taking Cosette "to the next phase of corporate growth by maximizing current and acquired assets." "David's appointment reflects Cosette's continued investment in commercial capabilities required to support the next level of growth." Apurva Saraf, President and CEO, Cosette Pharmaceuticals Bell also mentioned the importance of expanding patient access to key medicines, and alleviating patient and family burdens and suffering. Cosette President and CEO Apurva Saraf said the appointment reflects the company's investment in commercial capabilities to support next-level growth. "[Bell's] deep expertise in commercial strategy, market access, portfolio management, and P&L leadership will be valuable," Saraf said. "We continue to strengthen our branded portfolio and integrate new assets." New Cosette CCO's experience. Bell most recently served as Vice President, Business Unit Head, U.S. Oncology at Ferring Pharmaceuticals. There, he held full P&L ownership responsibility in the United States. He was also General Manager at Melinta Therapeutics. Prior to that, Bell spent 17 years at Schering-Plough/Merck & Co., holding regional, U.S., and global commercial leadership roles. He has additionally served as a board member of Enhanced HealthCare Solutions. Altogether, Bell brings to Cosette more than a quarter-century of leadership experience in oncology, rare disease, and gene therapy.
Cosette Pharmaceuticals appoints David Bell as Chief Commercial Officer (Brands). - Proven biopharmaceutical executive to lead commercial strategy as Cosette scales its branded pharmaceutical platform and advances its next phase of growth - BRIDGEWATER, N.J.-(BUSINESS WIRE)-#cosettepharma-Cosette Pharmaceuticals, Inc., a U.S.-based, branded specialty pharmaceutical company, announced today it has appointed David Bell as Chief Commercial Officer (Brands). David joins the company's executive leadership team as it continues to advance its ambitions in specialty pharmaceuticals and expand its commercial platform and portfolio. In this new role, David will oversee all branded commercial functions - including sales, marketing, market access, commercial operations, analytics, and portfolio strategy. He will be responsible for driving performance across Cosette's marketed portfolio of 21 brands, supporting the integration and growth of acquired assets, and ensuring strong alignment between commercial execution and the company's broader strategic and financial objectives. "David's appointment reflects Cosette's continued investment in the commercial capabilities required to support the next level of growth," said Apurva Saraf, President and CEO of Cosette Pharmaceuticals. "His deep expertise in commercial strategy, market access, portfolio management, and P&L leadership will be valuable as we continue to strengthen our branded portfolio and integrate new assets." David brings more than 25 years of commercial and enterprise leadership experience across oncology, rare disease and gene therapy in specialty pharmaceuticals markets. Most recently, David served as Vice President, Business Unit Head, US Oncology at Ferring Pharmaceuticals, where he held full U.S. P&L ownership responsibility. He also previously served as Franchise General Manager at Melinta Therapeutics and spent 17 years at Merck & Co. / Schering-Plough in progressive global, U.S., and regional commercial leadership roles. "I am proud to join Cosette, an organization that has built a differentiated platform with brands that help patients live better lives," David shared. "I am excited to join a leadership team that will take Cosette's branded portfolio to the next phase of corporate growth by maximizing current and acquired assets, expanding patient access to important medicines, and alleviating the burden and suffering of patients and their families." David earned his Master of Business Administration and Bachelor of Science in Finance from Seton Hall University's W. Paul Stillman School of Business. He also served as a board member of Enhanced HealthCare Solutions. About Cosette Pharmaceuticals Cosette Pharmaceuticals, Inc. is a U.S.-based, leading specialty pharmaceutical company providing some of the most trusted and well-known brands in medicine - developing and delivering products that make a difference in patients' lives. Cosette's strong growth has been driven by its best-in-class marketing, promotion, and strategic distribution capabilities, enabling the company to scale efficiently while continuing to invest in high-quality, patient-centered therapies. Cosette has corporate headquarters in Bridgewater, New Jersey and is supported by 350+ dedicated team members across all functional areas. Cosette is backed by Avista Healthcare Partners, a healthcare focused private equity firm, and funds managed by Hamilton Lane, a private markets investment management firm (Nasdaq: HLNE). For more information, please visit www.cosettepharma.com or follow Cosette on LinkedIn. Editor details. * Company: * Businesswire Last Updated: 19-May-2026
Ferring Pharmaceuticals and Gallup announce landmark global public attitudes study on fertility and family-building. Ferring Pharmaceuticals * Ferring Global Fertility Monitor will gather data from a representative sample in 70 countries as a part of the Gallup World Poll * Consultation to gather expert opinion on high impact questions begins this year * The project aims to provide data and evidence to inform demography-related policymaking against a backdrop of total fertility rates dropping below replacement levels in many countries worldwide, with the U.S. reporting its lowest on record in the latest federal data released last week[1] WASHINGTON-BUSINESS WIRE- Ferring Pharmaceuticals and Gallup today announced the Ferring Global Fertility Monitor, a global study on the factors influencing people's fertility choices, at the 2026 Annual Convening of Semafor World Economy. The Ferring Global Fertility Monitor is grounded in the recognition that declining global fertility rates are an increasingly significant public policy topic, with rates already well below replacement level in many countries. Rolled out as part of the Gallup World Poll, it will provide policymakers with robust, globally comparable data on the social, economic, cultural, and structural factors shaping fertility choices. By integrating these insights with people's lived experiences, well-being, and aspirations, the Monitor supports more responsive, inclusive, and human-centred approaches to demographic change. Jean-Frédéric Paulsen, Chairman of the Board of Directors and Chief Executive Officer of Ferring Pharmaceuticals, said: "As a company committed to supporting people on their fertility journey, we see the global debate on demographic change as one of the defining issues of our time. Around the world, questions about the future shape of populations are intensifying, yet the data needed to fully understand these shifts, and their implications, remains far too limited. This project has the potential to transform that landscape. By strengthening the global evidence base, we can deepen understanding of what is happening and why, helping governments, health systems and communities plan for a more sustainable future." Jon Clifton, Chief Executive Officer of Gallup, said: "We spend a lot of time debating falling fertility and birth rates, but surprisingly little time asking people why. This initiative changes that, using nationally representative data, collected consistently at a scale no one has attempted before across 70 countries." In 2026, the Ferring Global Fertility Monitor will be developed through an expert consultation and research process designed to identify critical evidence gaps in how fertility decisions are understood across countries. A cognitively tested questionnaire will then enter the 2027 Gallup World Poll and run as a biannual tracker. When complete, the Monitor will represent one of the most comprehensive global data and evidence bases to date on how people think about parenthood, and what helps or hinders them from realising those aspirations. The Gallup World Poll is the world's largest private survey infrastructure, collecting annual data from around 140 countries. All data are nationally representative of the adult population and collected either via face-to-face or telephone interviewing. The World Poll collects data on a wide range of topics, all of which speak to how people's lives are going. About Gallup Gallup delivers analytics and advice to help leaders and organisations solve their most pressing problems. Combining more than 85 years of experience and a global reach, Gallup knows more about the attitudes and behaviours of employees, customers, students and citizens than any other organisation in the world. About Ferring Pharmaceuticals Ferring Pharmaceuticals a privately owned, specialty biopharmaceutical group committed to building families and helping people live better lives. Connectweb is leaders in reproductive medicine with a strong heritage in gastroenterology and urology, and are at the forefront of innovation in uro-oncology gene therapy. Ferring was founded in 1950 and employs more than 7,500 people worldwide. The company is headquartered in Saint-Prex, Switzerland, and has operating subsidiaries in more than 50 countries which market its medicines in over 100 countries. [1] National Vital Statistics System; Births: Provisional Data for 2025; Report No.43; April 2026: Vital Statistics Rapid Release, Number 043 (April 2026) (Accessed April 2026) Contact details: Ferring Pharmaceuticals EU - Matthew Worrall, +44 7442 271 811, [email protected] EU - Mary Knight, +44 7747 758 437, [email protected] US - Lisa Perdomo, +1 (862) 341-9820, [email protected] Gallup US - Riada Asimovic Akyol, +1 (202) 715-3095, [email protected] * Images - Ferring_RGB_Logo_JPG.jpg Download - Gallup_logo_black.jpg Download
Ferring Service Center expansion. Ferring continues to grow its investment in Portugal. Ferring/AICEP 26/03/2026 The Ferring Service Center has recently expanded its office space, further reinforcing its commitment to offering a healthy, inclusive, and highly collaborative work environment for all employees. This expansion increases its capacity and positions Portugalglobal to continue growing in a strong and sustainable way.